(redirected from Fluticasone)
Also found in: Dictionary, Medical, Wikipedia.
FLUTFeline Lower Urinary Tract Disease
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
Fluticasone lotion is applied once-daily, which enhances compliance and promotes greater efficacy, which makes for happy parents, he continued.
"With the delivery of fluticasone cream we are ensuring, again, that quality prescription alternatives are available to those who need them."
* STUDY DESIGN AND VALIDITY Ninety-five patients were randomly assigned in a double-blind fashion (concealed allocation assignment) to receive 2 puffs (200 [micro]g/day) of fluticasone propionate (Flonase) or identical plat,elm nasal spray in each nostril once daily for 21 days.
In addition, an FDA meta-analysis of asthma-related serious adverse events in the four studies found a numerical imbalance in hospitalizations among adolescents: four hospitalizations among those on the combination drug, but none on fluticasone alone.
This appears to be a repackaging of fluticasone, which is marketed as Flonase [fluticasone propionate] by GlaxoSmithKline," Dr.
This study shows that for as-needed treatment of allergic rhinitis, fluticasone propionate appears to be superior to loratadine in both subjective and objective measurements.
No significant differences in resolution of esophageal eosinophilia were observed between the fluticasone group and the esomeprazole group.
There are three approved dosage strengths of the combination dry powder formulation marketed as Advair Diskus by GlaxoSmithKline (GSK): 100 / 50, 250 / 50, and 500/50, which contain 100 mcg, 250 mcg, and 500 mcg of the fluorinated corticosteroid fluticasone, respectively, each with 50 mcg of salmeterol, a long-acting [beta]-agonist.
SAN DIEGO--Once-daily fluticasone furoate nasal spray improves quality of life in people who suffer from seasonal allergic rhinitis, Dr.
Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.
Healthcare company GlaxoSmithKline plc (LSE:GSK) (NYSE:GSK) and Innoviva Inc (NASDAQ:INVA) on Monday announced the receipt of approval from the US Food and Drug Administration (FDA) for fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) therapy for the treatment of chronic obstructive pulmonary disease (COPD).